RTW INVESTMENTS, LP - Q1 2015 holdings

$222 Billion is the total value of RTW INVESTMENTS, LP's 24 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 52.4% .

 Value Shares↓ Weighting
ALNY BuyAlnylam Pharmaceuticals Inc$37,110,000
+12.4%
355,395
+4.4%
16.75%
+37.1%
DYAX SellDyax Corp$26,558,000
-11.4%
1,585,098
-25.6%
11.99%
+8.1%
DRNA SellDicerna Pharmaceuticals Inc$23,813,000
+29.6%
990,981
-11.2%
10.75%
+58.1%
KITE NewKite Pharma Inc$21,666,000375,623
+100.0%
9.78%
BCRX  BioCryst Pharmaceuticals Inc$20,420,000
-25.7%
2,261,3610.0%9.22%
-9.4%
LJPC  La Jolla Pharmaceutical Co$19,476,000
-0.8%
1,064,2470.0%8.79%
+21.0%
ARWR SellArrowhead Research Corp$16,304,000
-15.4%
2,410,000
-7.7%
7.36%
+3.3%
ACHN  Achillion Pharmaceuticals Inc$15,999,000
-19.5%
1,622,6330.0%7.22%
-1.8%
BLUE Newbluebird bio Inc$12,077,000100,000
+100.0%
5.45%
TRGT  Targacept Inc$7,917,000
+12.9%
2,665,6430.0%3.57%
+37.8%
ZSPH SellZS Pharma Inc$3,001,000
-80.7%
71,315
-81.0%
1.36%
-76.5%
ASMB  Assembly Biosciences Inc$2,701,000
+68.5%
204,0000.0%1.22%
+105.6%
LENS NewPresbia Plc$2,587,000350,000
+100.0%
1.17%
AAVL BuyAvalanche Biotechnologies In$2,079,000
-23.0%
51,300
+2.6%
0.94%
-6.0%
RPRX  Repros Therapeutics Inc$1,970,000
-13.9%
229,3640.0%0.89%
+5.1%
CNDO NewCoronado Biosciences Inc$1,925,000500,000
+100.0%
0.87%
CYTR SellCytRx Corp$1,900,000
-1.7%
563,814
-20.0%
0.86%
+20.0%
LPCN  Lipocine Inc$1,444,000
+31.2%
209,3330.0%0.65%
+60.2%
TARO SellTaro Pharmaceutical Industries Ltd$1,230,000
-96.9%
8,721
-96.7%
0.56%
-96.2%
RLYP SellRelypsa Inc$1,150,000
-91.7%
31,872
-92.9%
0.52%
-89.9%
LPTN  Lpath Inc$148,000
-12.4%
60,0000.0%0.07%
+6.3%
SHAK NewShake Shack Inc$25,000500
+100.0%
0.01%
TENX NewTenax Therapeutics Inc$8,0002,400
+100.0%
0.00%
BRKB NewBerkshire Hathaway Inc$7,00050
+100.0%
0.00%
NVRO ExitNEVRO CORP$0-15,356
-100.0%
-0.22%
PLX ExitPROTALIX BIOTHERAPEUTICS INC$0-843,851
-100.0%
-0.58%
VNDA ExitVANDA PHARMACEUTICALS INC$0-500,000
-100.0%
-2.65%
XNPT ExitXENOPORT INC$0-842,568
-100.0%
-2.73%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2015-05-21
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ALNYLAM PHARMACEUTICALS INC36Q3 202319.7%
MASIMO CORP32Q3 20235.8%
LA JOLLA PHARMACEUTICAL CO31Q2 20229.7%
REGENXBIO INC30Q4 202210.8%
AGENUS INC29Q2 20229.0%
PTC THERAPEUTICS INC28Q3 202312.8%
DICERNA PHARMACEUTICALS INC28Q3 202110.8%
MIRATI THERAPEUTICS INC26Q3 20236.2%
ARGENX SE26Q3 20235.3%
VERICEL CORP24Q3 20233.9%

View RTW INVESTMENTS, LP's complete holdings history.

Latest significant ownerships (13-D/G)
RTW INVESTMENTS, LP Q1 2015 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
ROCKET PHARMACEUTICALS, INC.September 19, 202318,188,457-
ALLURION TECHNOLOGIES, INC.August 11, 20233,457,7077.4%
Orchestra BioMed Holdings, Inc.May 05, 20235,620,64515.7%
Renovacor, Inc.Sold outApril 05, 20230-
Adverum Biotechnologies, Inc.Sold outFebruary 14, 202300.0%
Aptevo Therapeutics Inc.Sold outFebruary 14, 202300.0%
ASLAN Pharmaceuticals LtdSold outFebruary 14, 202300.0%
Athira Pharma, Inc.Sold outFebruary 14, 202300.0%
BELLUS Health Inc.Sold outFebruary 14, 202300.0%
Clearside Biomedical, Inc.Sold outFebruary 14, 202300.0%

View RTW INVESTMENTS, LP's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D/A2024-04-17
SC 13D/A2024-03-01
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View RTW INVESTMENTS, LP's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported total value is incorrect (221515021000.0 != 221515000.0)

Export RTW INVESTMENTS, LP's holdings